EA201891526A3 - Ингибиторы лизин-специфической деметилазы-1 - Google Patents
Ингибиторы лизин-специфической деметилазы-1Info
- Publication number
- EA201891526A3 EA201891526A3 EA201891526A EA201891526A EA201891526A3 EA 201891526 A3 EA201891526 A3 EA 201891526A3 EA 201891526 A EA201891526 A EA 201891526A EA 201891526 A EA201891526 A EA 201891526A EA 201891526 A3 EA201891526 A3 EA 201891526A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- compounds
- compositions
- lysine
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Настоящее изобретение в общем относится к композициям и способам для лечения ракового заболевания и неопластического заболевания. В данной заявке предусмотрены замещённые производные гетероциклических заболеваний и фармацевтические композиции, содержащие указанные соединения. Такие соединения и композиции полезны для ингибирования лизин-специфической деметилазы-1. Кроме того, заявляемые соединения и композиции пригодны для лечения рака, такого как рак простаты, рак молочной железы, рак мочевого пузыря, рак лёгкого и/или меланомы и т.п.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020886P | 2014-07-03 | 2014-07-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201891526A2 EA201891526A2 (ru) | 2018-12-28 |
| EA201891526A3 true EA201891526A3 (ru) | 2019-05-31 |
Family
ID=55019883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790085A EA033698B1 (ru) | 2014-07-03 | 2015-06-29 | Ингибиторы лизинспецифической деметилазы-1 |
| EA201891526A EA201891526A3 (ru) | 2014-07-03 | 2015-06-29 | Ингибиторы лизин-специфической деметилазы-1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201790085A EA033698B1 (ru) | 2014-07-03 | 2015-06-29 | Ингибиторы лизинспецифической деметилазы-1 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9902719B2 (ru) |
| EP (2) | EP3164380B1 (ru) |
| JP (2) | JP6663866B2 (ru) |
| KR (1) | KR102475498B1 (ru) |
| CN (2) | CN108530424B (ru) |
| AU (1) | AU2015284383B2 (ru) |
| BR (1) | BR112017000043A2 (ru) |
| CA (1) | CA2954049A1 (ru) |
| CL (1) | CL2016003422A1 (ru) |
| CO (1) | CO2017000549A2 (ru) |
| DK (2) | DK3511319T3 (ru) |
| EA (2) | EA033698B1 (ru) |
| EC (1) | ECSP17006821A (ru) |
| ES (2) | ES2948782T3 (ru) |
| FI (1) | FI3511319T3 (ru) |
| HR (2) | HRP20230595T1 (ru) |
| HU (2) | HUE062558T2 (ru) |
| IL (2) | IL249881B (ru) |
| LT (2) | LT3511319T (ru) |
| MX (2) | MX2020010900A (ru) |
| PL (2) | PL3164380T3 (ru) |
| PT (2) | PT3511319T (ru) |
| RS (2) | RS63074B1 (ru) |
| SA (1) | SA517380651B1 (ru) |
| SG (2) | SG11201610975RA (ru) |
| SI (2) | SI3164380T1 (ru) |
| WO (1) | WO2016003917A1 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180284095A1 (en) | 2015-06-12 | 2018-10-04 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| KR20230042756A (ko) | 2016-03-15 | 2023-03-29 | 오리존 지노믹스 에스.에이. | 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물 |
| JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ標的会合を決定するための方法、およびそれに有用な化学プローブ |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| SG11202000077RA (en) | 2017-08-03 | 2020-02-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| SG11202100199UA (en) * | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
| WO2020188089A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| BR112021016064A2 (pt) | 2019-03-20 | 2021-10-05 | Oryzon Genomics, S.A. | Métodos de tratamento do transtorno de personalidade borderline |
| EP3994280A1 (en) | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| US11360505B2 (en) | 2020-02-11 | 2022-06-14 | Simmonds Precision Products, Inc. | Distributed network time synchronization |
| CN114105950B (zh) * | 2020-08-31 | 2022-09-06 | 南京明德新药研发有限公司 | 吡唑类化合物及其应用 |
| CN117062813A (zh) * | 2021-03-24 | 2023-11-14 | 四川汇宇制药股份有限公司 | 一种多环化合物及其应用 |
| JP2024513260A (ja) | 2021-04-08 | 2024-03-22 | オリゾン ジェノミックス ソシエダッド アノニマ | 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ |
| CN116102533A (zh) * | 2021-11-11 | 2023-05-12 | 中国科学院上海药物研究所 | 一种芳杂环类化合物及其应用 |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963188A1 (de) * | 1969-12-17 | 1971-06-24 | Bayer Ag | Neue Cyanphenyl-1,4-dihydropyridinderivate |
| WO2002026718A2 (en) * | 2000-09-29 | 2002-04-04 | Millennium Pharmaceutical, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
| JP2005170792A (ja) * | 2002-11-22 | 2005-06-30 | Mitsubishi Pharma Corp | Ｌ−プロリン誘導体およびその医薬としての用途。 |
| EP1695969A4 (en) * | 2003-12-11 | 2008-11-26 | Mitsubishi Tanabe Pharma Corp | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE |
| WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| PL372332A1 (pl) * | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| BRPI0615048A2 (pt) * | 2005-09-01 | 2010-03-30 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| JP2007197324A (ja) | 2006-01-23 | 2007-08-09 | Toray Ind Inc | ２，４，５−置換−１，３−アゾール誘導体 |
| TW200815428A (en) * | 2006-08-15 | 2008-04-01 | Wyeth Corp | Oxazolidone derivatives as PR modulators |
| WO2008021309A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Imidazolidin-2-one derivatives useful as pr modulators |
| PE20081803A1 (es) | 2007-03-09 | 2008-12-11 | Wyeth Corp | Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| WO2009132310A1 (en) * | 2008-04-25 | 2009-10-29 | Wisconsin Alumni Research Foundation | Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth |
| US20130096160A1 (en) | 2010-04-14 | 2013-04-18 | Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| CA2866015A1 (en) * | 2012-03-06 | 2013-09-12 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
| HUE061252T2 (hu) * | 2013-12-11 | 2023-05-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibítorok |
| BR112016018691A2 (pt) * | 2014-02-14 | 2017-08-08 | Univ British Columbia | Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso |
| RS62874B1 (sr) * | 2014-05-01 | 2022-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| FR3020945B1 (fr) | 2014-05-16 | 2016-05-06 | Oreal | Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier |
| KR102438302B1 (ko) * | 2014-06-27 | 2022-08-30 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| CA2954060A1 (en) * | 2014-07-03 | 2016-01-07 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
-
2015
- 2015-06-29 KR KR1020177003162A patent/KR102475498B1/ko active IP Right Grant
- 2015-06-29 SI SI201531797T patent/SI3164380T1/sl unknown
- 2015-06-29 PT PT191569763T patent/PT3511319T/pt unknown
- 2015-06-29 RS RS20220311A patent/RS63074B1/sr unknown
- 2015-06-29 HU HUE19156976A patent/HUE062558T2/hu unknown
- 2015-06-29 HR HRP20230595TT patent/HRP20230595T1/hr unknown
- 2015-06-29 CN CN201810425583.0A patent/CN108530424B/zh active Active
- 2015-06-29 LT LTEP19156976.3T patent/LT3511319T/lt unknown
- 2015-06-29 SI SI201531948T patent/SI3511319T1/sl unknown
- 2015-06-29 SG SG11201610975RA patent/SG11201610975RA/en unknown
- 2015-06-29 BR BR112017000043-1A patent/BR112017000043A2/pt not_active Application Discontinuation
- 2015-06-29 US US15/323,277 patent/US9902719B2/en active Active
- 2015-06-29 ES ES19156976T patent/ES2948782T3/es active Active
- 2015-06-29 HR HRP20220414TT patent/HRP20220414T1/hr unknown
- 2015-06-29 PT PT158140384T patent/PT3164380T/pt unknown
- 2015-06-29 MX MX2020010900A patent/MX2020010900A/es unknown
- 2015-06-29 JP JP2016575768A patent/JP6663866B2/ja active Active
- 2015-06-29 EP EP15814038.4A patent/EP3164380B1/en active Active
- 2015-06-29 EA EA201790085A patent/EA033698B1/ru not_active IP Right Cessation
- 2015-06-29 LT LTEPPCT/US2015/038345T patent/LT3164380T/lt unknown
- 2015-06-29 DK DK19156976.3T patent/DK3511319T3/da active
- 2015-06-29 DK DK15814038.4T patent/DK3164380T3/da active
- 2015-06-29 CN CN201580047448.1A patent/CN106795103B/zh active Active
- 2015-06-29 CA CA2954049A patent/CA2954049A1/en not_active Abandoned
- 2015-06-29 SG SG10201802501RA patent/SG10201802501RA/en unknown
- 2015-06-29 ES ES15814038T patent/ES2907676T3/es active Active
- 2015-06-29 AU AU2015284383A patent/AU2015284383B2/en not_active Ceased
- 2015-06-29 PL PL15814038T patent/PL3164380T3/pl unknown
- 2015-06-29 EP EP19156976.3A patent/EP3511319B1/en active Active
- 2015-06-29 HU HUE15814038A patent/HUE058852T2/hu unknown
- 2015-06-29 FI FIEP19156976.3T patent/FI3511319T3/fi active
- 2015-06-29 PL PL19156976.3T patent/PL3511319T3/pl unknown
- 2015-06-29 RS RS20230452A patent/RS64423B1/sr unknown
- 2015-06-29 WO PCT/US2015/038345 patent/WO2016003917A1/en active Application Filing
- 2015-06-29 EA EA201891526A patent/EA201891526A3/ru unknown
- 2015-06-29 MX MX2017000168A patent/MX2017000168A/es active IP Right Grant
-
2016
- 2016-12-30 CL CL2016003422A patent/CL2016003422A1/es unknown
-
2017
- 2017-01-01 IL IL249881A patent/IL249881B/en active IP Right Grant
- 2017-01-02 SA SA517380651A patent/SA517380651B1/ar unknown
- 2017-01-23 CO CONC2017/0000549A patent/CO2017000549A2/es unknown
- 2017-02-01 EC ECIEPI20176821A patent/ECSP17006821A/es unknown
-
2018
- 2018-01-10 US US15/867,397 patent/US10100046B2/en active Active
- 2018-09-05 US US16/122,703 patent/US20190002456A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029856A patent/JP6768857B2/ja active Active
-
2020
- 2020-01-19 IL IL272130A patent/IL272130B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891526A3 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201790376A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201692513A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| EA201591145A1 (ru) | Ингибиторы гистондеметилазы | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA201691940A1 (ru) | Новые соединения | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| CR20200362A (es) | CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395) | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
| EA201790603A1 (ru) | Ингибиторы гистондеметилазы | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) | |
| EA201790445A1 (ru) | Производные индолинона и их применение | |
| EA201790604A1 (ru) | Ингибиторы гистондеметилазы | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| EA201991746A1 (ru) | Производные пиразола в качестве ингибиторов бромодомена | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| EA201990556A1 (ru) | Ингибиторы клеточных метаболических процессов |